Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC)
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer ABATE study
Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study
A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients
A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC)
Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of HCRN GU14-188
Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC)
Phase 1b/2 Multicenter Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer (NCT02365766)
Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC)
Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC)
Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression
Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC)
Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma
A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB)
A Phase II Trial of Neoadjuvant Cisplatin (C), Gemcitabine (G), and Sunitinib (S) in Muscle-Invasive Urothelial Carcinoma (miUC)
Mature results from phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)
A Phase III Trial of Thoracic Irradiation with or without Cisplatin for Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC)
A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Final results of a phase I study of amrubicin and cyclophosphamide in patients with advanced solid organ malignancies
Prophylactic 32P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke’s Stage C Colon Cancers
A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Study
